References
- Abraham, A. J., Andrews, C. M., Harris, S. J., & Friedmann, P. D. (2020). Availability of medications for the treatment of alcohol and opioid use disorder in the USA. Neurotherapeutics, 17(1), 55–69. https://doi.org/https://doi.org/10.1007/s13311-019-00814-4
- Ackerman, B. (2018). A qualitative study of counseling students’ attitudes toward the use of medication assisted treatments with opioid dependent clients. Duquesne University.
- Aletraris, L., Edmond, M. B., Paino, M., Fields, D., & Roman, P. M. (2016). Counselor training and attitudes toward pharmacotherapies for opioid use disorder. Substance Abuse, 37(1), 47–53. https://doi.org/https://doi.org/10.1080/08897077.2015.1062457
- Beachler, T., Zeller, T. A., Heo, M., Lanzillotta‐Rangeley, J., & Litwin, A. H. (2021). Community attitudes toward opioid use disorder and medication for opioid use disorder in a rural Appalachian County. The Journal of Rural Health, 37(1), 29–34. https://doi.org/https://doi.org/10.1111/jrh.12503
- Bride, B. E., Abraham, A. J., Kintzle, S., & Roman, P. M. (2013). Social workers’ knowledge and perceptions of effectiveness and acceptability of medication assisted treatment of substance use disorders. Social Work in Health Care, 52(1), 43–58. https://doi.org/https://doi.org/10.1080/00981389.2012.725457
- Edwards, K. T., & Palmer, K. (2020). Barriers to substance use disorder treatment in a sub-acute setting. Journal of Social Work Practice in the Addictions, 20(2), 174–178. https://doi.org/https://doi.org/10.1080/1533256X.2020.1749366
- Figgatt, M. C., Salazar, Z., Day, E., Vincent, L., & Dasgupta, N. (2021). Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19. Journal of Substance Abuse Treatment, 123, 108276. https://doi.org/https://doi.org/10.1016/j.jsat.2021.108276
- Koehl, J. L., Zimmerman, D. E., & Bridgeman, P. J. (2019). Medications for management of opioid use disorder. American Journal of Health-System Pharmacy, 76(15), 1097–1103. https://doi.org/https://doi.org/10.1093/ajhp/zxz105
- Krawczyk, N., Negron, T., Nieto, M., Agus, D., & Fingerhood, M. I. (2018). Overcoming medication stigma in peer recovery: A new paradigm. Substance Abuse, 39(4), 404–409. https://doi.org/https://doi.org/10.1080/08897077.2018.1439798
- Kvaale, E. P., Gottdiener, W. H., & Haslam, N. (2013). Biogenetic explanations and stigma: A meta-analytic review of associations among laypeople. Social Science & Medicine, 96, 95–103. https://doi.org/https://doi.org/10.1016/j.socscimed.2013.07.017
- Leshner, A. I., & Mancher, M. (Eds.). (2019). Medications for opioid use disorder save lives. National Academy of Sciences.
- Lofwall, M. R., & Walsh, S. L. (2014). A review of buprenorphine diversion and misuse: The current evidence base and experiences from around the world. Journal of Addiction Medicine, 8(5), 315–326. https://doi.org/https://doi.org/10.1097/ADM.0000000000000045
- Quinn, D. M., & Chaudoir, S. R. (2009). Living with a concealable stigmatized identity: The impact of anticipated stigma, centrality, salience, and cultural stigma on psychological distress and health. Journal of Personality and Social Psychology, 97(4), 634–651. https://doi.org/https://doi.org/10.1037/a0015815
- Richard, E. L., Schalkoff, C. A., Piscalko, H. M., Brook, D. L., Sibley, A. L., Lancaster, K. E., Miller, W. C., & Go, V. F. (2020). “You are not clean until you’re not on anything”: Perceptions of medication-assisted treatment in rural Appalachia. International Journal of Drug Policy, 85, 102704. https://doi.org/https://doi.org/10.1016/j.drugpo.2020.102704
- Singh, S., Kumar, S., Sarkar, S., & Balhara, Y. P. S. (2018). Quality of life and its relationship with perceived stigma among opioid use disorder patients: An exploratory study. Indian Journal of Psychological Medicine, 40(6), 556–561. https://doi.org/https://doi.org/10.4103/IJPSYM.IJPSYM_171_18
- Stone, E. M., Kennedy-Hendricks, A., Barry, C. L., Bachhuber, M. A., & McGinty, E. E. (2021). The role of stigma in U.S. primary care physicians’ treatment of opioid use disorder. Drug and Alcohol Dependence, 221, 108627. https://doi.org/https://doi.org/10.1016/j.drugalcdep.2021.108627
- Tsai, A. C., Kiang, M. V., Barnett, M. L., Beletsky, L., Keyes, K. M., McGinty, E. E., Smith, L. R., Strathdee, S. A., Wakeman, S. E., & Venkataramani, A. S. (2019). Stigma as a fundamental hindrance to the United States opioid overdose crisis response. PLOS Medicine, 16(11), e1002969. https://doi.org/https://doi.org/10.1371/journal.pmed.1002969
- Uebelacker, L. A., Bailey, G., Herman, D., Anderson, B., & Stein, M. (2016). Patients’ beliefs about medications are associated with stated preference for methadone, buprenorphine, naltrexone, or no medication-assisted therapy following inpatient opioid detoxification. Journal of Substance Abuse Treatment, 66, 48–53. https://doi.org/https://doi.org/10.1016/j.jsat.2016.02.009
- Wakeman, S. E., Larochelle, M. R., Ameli, O., Chaisson, C. E., Thomas Mcpheeters, J., Crown, W. H., Azocar, F., & Sanghavi, D. M. (2020). Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Network Open, 3(2), 1–12. https://doi.org/https://doi.org/10.1001/jamanetworkopen.2019.20622
- Williams, A. R., Nunes, E. V., Bisaga, A., Pincus, H. A., Johnson, K. A., Campbell, A. N., Remien, R. H., Crystal, S., Friedmann, P. D., Levin, F. R., & Olfson, M. (2018). Developing an opioid use disorder treatment cascade: A review of quality measures. Journal of Substance Abuse Treatment, 91, 57–68. https://doi.org/https://doi.org/10.1016/j.jsat.2018.06.001
- Woo, J., Bhalerao, A., Bawor, M., Bhatt, M., Dennis, B., Mouravska, N., Zielinski, L., & Samaan, Z. (2017). “Don’t judge a book by its cover”: A qualitative study of methadone patients’ experiences of stigma. Substance Abuse: Research and Treatment, 11, 117822181668508. https://doi.org/https://doi.org/10.1177/1178221816685087